Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Contrast-induced Nephropathy in Extra-cardiac Vascular Procedures – A Call to Action

Author(s): Lisa Aimee Hechanova and Debabrata Mukherjee*

Volume 20, Issue 1, 2022

Published on: 12 July, 2021

Page: [27 - 28] Pages: 2

DOI: 10.2174/1570161119666210712122757

« Previous Next »
[1]
Blandon J, Mukherjee D. Current approaches to prevention of contrast induced acute kidney injury. Cardiovasc Hematol Agents Med Chem 2011; 9: 247-52.
[2]
Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med 2018; 378: 603-14.
[3]
Palevsky PM, Liu KD, Brophy PD, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 2013; 61: 649-72.
[4]
Geenen RW, Kingma HJ, van der Molen AJ. Contrast-induced nephropathy: Pharmacology, pathophysiology and prevention. Insights Imaging 2013; 4: 811-20.
[5]
Grossman PM, Ali SS, Aronow HD, et al. Contrast-induced nephropathy in patients undergoing endovascular peripheral vascular intervention: Incidence, risk factors, and outcomes as observed in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. J Interv Cardiol 2017; 30: 274-80.
[6]
Raffort J, Lareyre F, Katsiki N, Mikhailidis D. Contrast-induced nephropathy in non-cardiac vascular procedures, a narrative review: Part 1. Curr Vasc Pharmacol 2022; 20(1): 3-15.
[7]
Raffort J, Lareyre F, Katsiki N, Mikhailidis D. Contrast-induced nephropathy in non-cardiac vascular procedures, a narrative review: Part 2. Curr Vasc Pharmacol 2022; 20(1): 16-26.
[8]
Sigterman TA, Krasznai AG, Snoeijs MG, Heijboer R, Schurink GW, Bouwman LH. Contrast induced nephropathy and long-term renal decline after percutaneous transluminal angioplasty for symptomatic peripheral arterial disease. Eur J Vasc Endovasc Surg 2016; 51: 386-93.
[9]
Maioli M, Toso A, Leoncini M, Gallopin M, Musilli N, Bellandi F. Persistent renal damage after contrast-induced acute kidney injury: incidence, evolution, risk factors, and prognosis. Circulation 2012; 125: 3099-107.
[10]
McCullough PA, Choi JP, Feghali GA, et al. Contrast-induced acute kidney injury. J Am Coll Cardiol 2016; 68: 1465-73.
[11]
Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Contrast-induced nephropathy: An “all or none” phenomenon? Angiology 2015; 66: 508-13.
[12]
Davenport MS, Perazella MA, Yee J, et al. Use of intravenous iodinated contrast media in patients with kidney disease: Consensus statements from the American college of radiology and the national kidney foundation. Radiology 2020; 294: 660-8.
[13]
Panagiotou A, Trendelenburg M, Heijnen I, et al. A randomized trial of recombinant human C1-esterase-inhibitor in the prevention of contrast-induced kidney injury. JACC Cardiovasc Interv 2020; 13: 833-42.

Rights & Permissions Print Cite
Article Metrics
18
6
© 2024 Bentham Science Publishers | Privacy Policy